Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Total Non-Current Liabilities (2020 - 2026)

Cytek Biosciences filings provide 6 years of Total Non-Current Liabilities readings, the most recent being $117.5 million for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 15.87% to $117.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $117.5 million, a 15.87% increase, with the full-year FY2025 number at $117.5 million, up 15.87% from a year prior.
  • Total Non-Current Liabilities hit $117.5 million in Q4 2025 for Cytek Biosciences, up from $113.8 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $117.5 million in Q4 2025 to a low of $46.2 million in Q2 2021.
  • Median Total Non-Current Liabilities over the past 5 years was $98.8 million (2023), compared with a mean of $90.7 million.
  • Biggest five-year swings in Total Non-Current Liabilities: skyrocketed 73.86% in 2022 and later decreased 6.1% in 2024.
  • Cytek Biosciences' Total Non-Current Liabilities stood at $56.7 million in 2021, then surged by 62.82% to $92.3 million in 2022, then grew by 7.17% to $99.0 million in 2023, then rose by 2.46% to $101.4 million in 2024, then rose by 15.87% to $117.5 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $117.5 million (Q4 2025), $113.8 million (Q3 2025), and $113.3 million (Q2 2025) per Business Quant data.